Creo Medical Group plc
("Creo", the "Company" or the "Group")
Grant of Options
Creo Medical Group plc (AIM: CREO), a medical device company focused on the emerging field of minimally invasive surgical endoscopy for pre-cancer and cancer patients, announces that on 24 March 2025, it granted options over an aggregate 6,474,713 ordinary shares of £0.001 in the Company (the "Options") to certain Directors of the Company as follows:
|
Name of Director |
Share Options Granted |
Exercise Price |
Total no. of options over ordinary shares now held |
|
Craig Gulliford |
2,062,500 |
£0.13125 |
9,970,001 |
|
Christopher Hancock |
1,384,063 |
£0.13125 |
7,832,637 |
|
Richard Rees |
1,410,938 |
£0.13125 |
6,066,870 |
|
David Woods |
1,617,212 |
£0.13125 |
3,712,322 |
Vesting of the options is subject to performance conditions through to December 2027.
For further information please contact:
|
Creo Medical Group plc |
||
|
Richard Craven, Company Secretary |
Via Walbrook PR |
|
|
Deutsche Numis (Nominated Adviser, sole Broker and Financial Adviser) Freddie Barnfield / Duncan Monteith / Euan Brown / Sher Shah |
+44 (0)20 7260 1000 |
|
|
Walbrook PR Ltd |
Tel: +44 (0)20 7933 8780 or creo@walbrookpr.com |
|
|
Paul McManus / Alice Woodings Phillip Marriage |
Mob: +44 (0)7980 541 893 / +44 (0)7407 804 654 Mob: +44 (0)7867 984 082 |
|
About Creo Medical
Creo is a medical device company focused on the development and commercialisation of minimally invasive electrosurgical devices, bringing advanced energy to endoscopy.
The Company's vision is to improve patient outcomes through the development and commercialisation of a suite of electrosurgical medical devices, each enabled by CROMA, powered by Kamaptive. The Group has developed the CROMA powered by Kamaptive full-spectrum adaptive technology to optimise surgical capability and patient outcomes. Kamaptive is a seamless, intuitive integration of multi-modal energy sources, optimised to dynamically adapt to patient tissue during procedures such as resection, dissection, coagulation, and ablation of tissue. Kamaptive technology provides clinicians with increased flexibility, precision and controlled surgical solutions. CROMA currently delivers bipolar radiofrequency ("RF") energy for precise localised cutting and focused high frequency microwave ("MW") energy for controlled coagulation and ablation via a single accessory port. This technology, combined with the Group's range of patented electrosurgical devices, is designed to provide clinicians with flexible, accurate and controlled clinical solutions. The Directors believe the Company's technology can impact the landscape of surgery and endoscopy by providing a safer, less invasive and more cost-efficient option for procedures.
For more information, please refer to the website www.creomedical.com
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them:
|
1 |
Details of the person discharging managerial responsibilities / person closely associated |
||||
|
a) |
Name |
Craig Gulliford |
|||
|
2 |
Reason for the notification |
||||
|
a) |
Position/status |
Chief Executive Officer |
|||
|
b) |
Initial notification /Amendment |
Initial notification |
|||
|
3 |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||||
|
a) |
Name |
Creo Medical Group plc |
|||
|
b) |
LEI |
213800H188ZDCWWXFA21 |
|||
|
4 |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
||||
|
a) |
Description of the financial instrument, type of instrument |
Ordinary shares of £0.001 each |
|||
|
Identification code |
GB00BZ1BLL44 |
||||
|
b) |
Nature of the transaction |
Grant of Options |
|||
|
c) |
Price(s) and volume(s) |
||||
|
Price(s) |
Volume(s) |
||||
|
Nil |
2,062,500 |
||||
|
d) |
Aggregated information |
||||
|
- Aggregated volume |
N/A - single transaction |
||||
|
- Price |
|||||
|
e) |
Date of the transaction |
24 March 2025 |
|||
|
f) |
Place of the transaction |
Off-market |
|||
|
1 |
Details of the person discharging managerial responsibilities / person closely associated |
|||||
|
a) |
Name |
Chris Hancock |
||||
|
2 |
Reason for the notification |
|||||
|
a) |
Position/status |
Chief Technology Officer |
||||
|
b) |
Initial notification /Amendment |
Initial notification |
||||
|
3 |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
|||||
|
a) |
Name |
Creo Medical Group plc |
||||
|
b) |
LEI |
213800H188ZDCWWXFA21 |
||||
|
4 |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
|||||
|
a) |
Description of the financial instrument, type of instrument |
Ordinary shares of £0.001 each |
||||
|
Identification code |
GB00BZ1BLL44 |
|||||
|
b) |
Nature of the transaction |
Grant of Options |
||||
|
c) |
Price(s) and volume(s) |
|
||||
|
d) |
Aggregated information |
|||||
|
- Aggregated volume |
N/A - single transaction |
|||||
|
e) |
Date of the transaction |
24 March 2025 |
||||
|
f) |
Place of the transaction |
Off-market |
||||
|
1 |
Details of the person discharging managerial responsibilities / person closely associated |
|||||
|
a) |
Name |
Richard Rees |
||||
|
2 |
Reason for the notification |
|||||
|
a) |
Position/status |
Chief Financial Officer |
||||
|
b) |
Initial notification /Amendment |
Initial notification |
||||
|
3 |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
|||||
|
a) |
Name |
Creo Medical Group plc |
||||
|
b) |
LEI |
213800H188ZDCWWXFA21 |
||||
|
4 |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
|||||
|
a) |
Description of the financial instrument, type of instrument |
Ordinary shares of £0.001 each |
||||
|
Identification code |
GB00BZ1BLL44 |
|||||
|
b) |
Nature of the transaction |
Grant of Options |
||||
|
c) |
Price(s) and volume(s) |
|
||||
|
d) |
Aggregated information |
|||||
|
- Aggregated volume |
N/A - single transaction |
|||||
|
e) |
Date of the transaction |
24 March 2025 |
||||
|
f) |
Place of the transaction |
Off-market |
||||
|
1 |
Details of the person discharging managerial responsibilities / person closely associated |
|||||
|
a) |
Name |
David Woods |
||||
|
2 |
Reason for the notification |
|||||
|
a) |
Position/status |
Chief Commercial Officer |
||||
|
b) |
Initial notification /Amendment |
Initial notification |
||||
|
3 |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
|||||
|
a) |
Name |
Creo Medical Group plc |
||||
|
b) |
LEI |
213800H188ZDCWWXFA21 |
||||
|
4 |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
|||||
|
a) |
Description of the financial instrument, type of instrument |
Ordinary shares of £0.001 each |
||||
|
Identification code |
GB00BZ1BLL44 |
|||||
|
b) |
Nature of the transaction |
Grant of Options |
||||
|
c) |
Price(s) and volume(s) |
|
||||
|
d) |
Aggregated information |
|||||
|
- Aggregated volume |
N/A - single transaction |
|||||
|
e) |
Date of the transaction |
24 March 2025 |
||||
|
f) |
Place of the transaction |
Off market |
||||